Skip to content
DraconiticResearch
Search Sources API
203,234 studies31 sourcesUpdated 45 min ago
Peer-reviewedCC BY 4.0Frontiers in Microbiology

CRISPR diagnostics for maternal–infant HIV, hepatitis B, and syphilis care: clinical roles and translational gaps

  • Hongzhi Luo1
  • Lanke Lin1
  • Fukang Luo1
  • Xiaoxue Huang2
  • Qiujie Yu3
  • Qianyi Li4
  • He Zha2
4 affiliations
  1. 1West China Hospital Sichuan University Jintang Hospital, Jintang First People’s Hospital
  2. 2Department of Laboratory Medicine, The Third Affiliated Hospital of Zunyi Medical University (The First People’s Hospital of Zunyi), Zunyi
  3. 3The Second Affiliated Hospital of Guizhou, University of Traditional Chinese Medicine
  4. 4Public Health Clinical Center of Chengdu
Read full textPDFDOICite

Abstract

This review asked which maternal–infant clinical decisions are plausible targets for CRISPR diagnostics, what evidence currently supports those roles, and what validation remains necessary. We conducted a structured narrative review of CRISPR diagnostics for HIV, hepatitis B virus (HBV), and syphilis, evaluating complete specimen-to-result systems rather than isolated nuclease reactions. Across the studies identified, HIV early infant diagnosis (EID) had the strongest near-term clinical rationale but lacked validation of microvolume whole blood or dried blood spots, broad HIV-1 inclusivity, and integrated process controls. Maternal HBV had the broadest clinical-specimen evidence, but no identified study established IU/mL-traceable classification around a pregnancy prophylaxis decision boundary. Syphilis direct detection supported a narrower specimen- and stage-dependent adjunctive role and could not replace antenatal serology or exclude congenital infection when negative. Major cross-cutting gaps included specimen preparation, calibration, contamination containment, invalid-result detection, and multisite intended-use validation. These findings do not establish routine clinical readiness. As an evidence-informed development priority, a shared service platform with separately validated pathogen-specific assays appears more defensible in the near term than a universal single-tube triplex.

Related

  1. The cadherin superfamily in pregnancy disorders: from maternal–fetal interface biology to translational opportunities
    Liubiqi Zhao, Fang Wang, Yanmei Xia +1
    Frontiers in ImmunologyPeer-reviewedCC BY 4.0ImmunologyFrontiers
  2. Clinical Long-Read Genome Sequencing for Rare-Disease Diagnostics
    Tessa J.J. de Bitter, Bart P. G. H. van der Sanden, Lydia Sagath +34
    New England Journal of MedicinePeer-reviewedLicence not statedFull text10 citedGenetics & genomicsOpenAlex
  3. Translational neuroscience in psychoeducation: Mapping nonmotor circuitry to clinical management in movement disorders
    Behzad Elahi
    PsyArXivPreprintAll rights reservedFull textNeuroscienceOSF
  4. Clinical trial landscape and translational priorities for adoptive T-cell and NK-cell therapies in gynecologic malignancies
    Qingyu Chen, Yuxin Zhu, Shilin Ye +2
    Frontiers in immunologyPeer-reviewedCC BYFull textImmunologyEurope PMC
  5. Centrosomal protein 55: Research progress on biological characteristics, disease associations and clinical translational potential (Review)
    Sanmei Nong, Qiudong Huang, Kuibo Huang +5
    International Journal of Molecular MedicinePeer-reviewedCC BY-NC-ND 4.0Full textCell biologyPMC

Cite

BibTeXRIS
BibTeX
@article{luo2026crispr,
  title = {{CRISPR diagnostics for maternal–infant HIV, hepatitis B, and syphilis care: clinical roles and translational gaps}},
  author = {Hongzhi Luo and Lanke Lin and Fukang Luo and Xiaoxue Huang and Qiujie Yu and Qianyi Li and He Zha},
  journal = {Frontiers in Microbiology},
  year = {2026},
  month = oct,
  doi = {10.3389/fmicb.2026.1977927},
  url = {https://www.frontiersin.org/articles/10.3389/fmicb.2026.1977927/full},
  note = {CC BY 4.0},
}
RIS
TY  - JOUR
TI  - CRISPR diagnostics for maternal–infant HIV, hepatitis B, and syphilis care: clinical roles and translational gaps
AU  - Hongzhi Luo
AU  - Lanke Lin
AU  - Fukang Luo
AU  - Xiaoxue Huang
AU  - Qiujie Yu
AU  - Qianyi Li
AU  - He Zha
PY  - 2026
DA  - 2026/10/21
JO  - Frontiers in Microbiology
DO  - 10.3389/fmicb.2026.1977927
UR  - https://www.frontiersin.org/articles/10.3389/fmicb.2026.1977927/full
AB  - This review asked which maternal–infant clinical decisions are plausible targets for CRISPR diagnostics, what evidence currently supports those roles, and what validation remains necessary. We conducted a structured narrative review of CRISPR diagnostics for HIV, hepatitis B virus (HBV), and syphilis, evaluating complete specimen-to-result systems rather than isolated nuclease reactions. Across the studies identified, HIV early infant diagnosis (EID) had the strongest near-term clinical rationale but lacked validation of microvolume whole blood or dried blood spots, broad HIV-1 inclusivity, and integrated process controls. Maternal HBV had the broadest clinical-specimen evidence, but no identified study established IU/mL-traceable classification around a pregnancy prophylaxis decision boundary. Syphilis direct detection supported a narrower specimen- and stage-dependent adjunctive role and could not replace antenatal serology or exclude congenital infection when negative. Major cross-cutting gaps included specimen preparation, calibration, contamination containment, invalid-result detection, and multisite intended-use validation. These findings do not establish routine clinical readiness. As an evidence-informed development priority, a shared service platform with separately validated pathogen-specific assays appears more defensible in the near term than a universal single-tube triplex.
SN  - 1664-302X
ER  -